Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
t-cell crawled time : 11:00 save search
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.781 -1.14% -1.15% 110K
|
Manufacturing
|
| O: -16.22%
H: 0.99%
C: -7.89%
first melanoma update therapeutics advanced
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
Published: 2024-02-08 (Crawled : 11:00) - globenewswire.com
BNTX | News | $88.53 0.59% 0.59% 360K
|
Health Technology
|
| O: 0.16%
H: 0.17%
C: -1.16%
AUTL | $4.5 -1.32% -1.33% 1.7M
|
Health Technology
|
| O: 2.85%
H: 0.0%
C: -7.69%
pipeline cell collaboration car-t therapy
GenFleet Therapeutics Announces GFH009 Granted with FDA Fast Track, Orphan Drug Designations for Treating R/R Peripheral T-cell Lymphomas and Acute Myeloid Leukemia
Published: 2024-01-11 (Crawled : 11:00) - prnewswire.com
SLS | $1.615 4.87% 4.64% 2M
|
Health Technology
|
| O: 1.84%
H: 1.25%
C: -4.34%
gfh009 fda drug t-cell granted lymphomas leukemia therapeutics
Generation Bio Announces Demonstration of Highly Selective T Cell Transduction In Vivo with Cell-Targeted LNP Platform
Published: 2023-10-26 (Crawled : 11:00) - globenewswire.com
MRNA | News S | $107.87 3.26% 3.16% 2.4M
|
Health Technology
|
| O: -0.04%
H: 0.64%
C: -0.98%
GBIO | News | $3.27 16.37% 14.07% 210K
|
Health Technology
|
| O: 1.28%
H: 2.11%
C: 0.85%
cell platform
Kymera Therapeutics Receives U.S. FDA Fast Track Designation for KT-333, a First-in-Class, Investigational STAT3 Degrader for the Treatment of Relapsed/Refractory Cutaneous T-Cell Lymphoma and Relapsed/Refractory Peripheral T-Cell Lymphoma
Published: 2023-09-18 (Crawled : 11:00) - globenewswire.com
KYMR | $35.7 3.93% 3.78% 440K
|
Health Technology
|
| O: 1.0%
H: 1.92%
C: -0.78%
kt-333 fda t-cell treatment designation therapeutics
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Published: 2023-08-09 (Crawled : 11:00) - globenewswire.com
CGEM | $16.645 6.49% 6.07% 970K
|
|
| O: 4.0%
H: 0.0%
C: 0.0%
cln-978 cell trial
Marker Therapeutics to Participate in Virtual Roundtable with Key Opinion Leaders to Discuss Clinical Landscape of CAR-T Cell Therapies on August 9, 2023
Published: 2023-07-26 (Crawled : 11:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 1.14%
H: 9.01%
C: -3.94%
cell car-t therapeutics
A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US
Published: 2023-07-06 (Crawled : 11:00) - prnewswire.com
GDTC | $2.205 -2.0% -2.04% 1.2K
|
|
| O: 3.11%
H: 8.72%
C: 3.03%
patent granted cell technology therapeutics
Genelux Corporation and TVAX Biomedical, Inc. announce the issuance of a United States patent covering the combination of an adoptive T cell therapy/oncolytic viral cancer treatment that is exclusively licensed to V2ACT Therapeutics™, LLC
Published: 2023-06-29 (Crawled : 11:00) - globenewswire.com
GNLX | $3.485 4.03% 3.87% 150K
|
|
| O: -0.03%
H: 3.07%
C: -1.54%
patent corporation cancer cell treatment
Autolus Therapeutics Presents Positive Results from AUTO4 in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma
Published: 2023-06-16 (Crawled : 11:00) - globenewswire.com
AUTL | $4.5 -1.32% -1.33% 1.7M
|
Health Technology
|
| O: 1.77%
H: 1.74%
C: 0.35%
t-cell positive therapeutics results
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma CellsMT-601 showed anti-tumor activity against CD19 CAR T refractory lymphoma cells in vitro
Published: 2023-05-31 (Crawled : 11:00) - biospace.com/
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 39.11%
H: 5.41%
C: -3.78%
mt-601 candidate pre-clinical cell cd19 therapeutics in vitro
Marker Therapeutics Reports Pre-Clinical Data of its MT-601 MultiTAA-Specific T Cell Product Candidate in Lymphoma Cells
Published: 2023-05-31 (Crawled : 11:00) - globenewswire.com
MRKR | $4.43 5.73% 5.42% 12K
|
Consumer Services
|
| O: 39.11%
H: 5.41%
C: -3.78%
mt-601 candidate pre-clinical cell therapeutics
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
Published: 2023-05-10 (Crawled : 11:00) - globenewswire.com
ACHL | $0.781 -1.14% -1.15% 110K
|
Manufacturing
|
| O: 5.0%
H: 0.0%
C: -9.42%
cell application platform
Adaptive Biotechnologies Announces FDA Acceptance of Genentech’s Investigational New Drug Application for the First Neoantigen-Directed T-Cell Therapy Product in Oncology
Published: 2023-05-09 (Crawled : 11:00) - globenewswire.com
ADPT | $2.575 2.59% 2.52% 1.5M
|
Commercial Services
|
| O: 0.76%
H: 9.17%
C: 5.41%
fda drug t-cell application therapy
Relief Therapeutics Announces IRB Approval of Investigator-Initiated Trial Evaluating RLF-TD011 as an Adjunctive Treatment for Cutaneous T-Cell Lymphom
Published: 2023-01-17 (Crawled : 11:00) - biospace.com/
RLFTF | $1.45 11.45% 1.3K
|
n/a
|
| O: -8.26%
H: 14.0%
C: 10.0%
td011 treatment t-cell trial approval therapeutics
Kite’s CAR T-cell Therapy Yescarta® Granted European Marketing Authorization for the Treatment of Relapsed or Refractory Follicular Lymphoma
Published: 2022-06-28 (Crawled : 11:00) - biospace.com/
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.14%
H: 1.05%
C: -0.99%
yescarta treatment t-cell granted authorization therapy
Citius Pharmaceuticals Reports Topline Data from the Pivotal Phase 3 Study of Cancer Immunotherapy I/ONTAK (E7777) for the Treatment of Persistent or Recurrent Cutaneous T-Cell Lymphoma (CTCL) in Support of BLA Submission
Published: 2022-04-06 (Crawled : 11:00) - prnewswire.com
CTXR | $0.772 5.15% 4.9% 670K
|
Health Technology
|
| O: 8.7%
H: 0.5%
C: -14.5%
treatment immunotherapy topline t-cell cancer submission e7777 ontak denileukin diftitox bla submission phase 3
Egle Therapeutics Raises 40 Million € Series a to Develop First-In-Class T-regulatory Cells Therapies Based On Treg-starvers
Published: 2021-10-22 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -1.1%
H: 0.0%
C: -0.41%
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: 0.07%
H: 0.5%
C: 0.29%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.41%
H: 0.0%
C: 0.0%
therapy
Adicet to Present Preclinical Data from Allogeneic Gamma Delta T Cell Platform at SITC 36th Annual Meeting
Published: 2021-10-04 (Crawled : 11:00) - globenewswire.com
ACET | News | $2.1 5.0% 4.76% 1.1M
|
Health Technology
|
| O: 1.63%
H: 2.22%
C: 0.87%
preclinical t-cell pre-clinical
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Published: 2021-06-11 (Crawled : 11:00) - globenewswire.com
MBIO | $0.3355 -1.32% -1.34% 120K
|
Health Technology
|
| O: 4.99%
H: 1.5%
C: -5.25%
FBIO | $1.79 2.29% 2.23% 190K
|
Health Technology
|
| O: 3.49%
H: 0.9%
C: 0.9%
phase 1 leukemia phase 3 car-t t-cell
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.